Engineered immune cells target blood cancers in groundbreaking trial
NCT ID NCT06704152
Summary
This study is testing a new cell therapy called BSB-1001 for adults with certain high-risk blood cancers (AML, ALL, or MDS). The goal is to see if giving these specially engineered immune cells after a donor stem cell transplant is safe and can help prevent the cancer from coming back. The study will enroll up to 38 patients who meet specific genetic and health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Washington University at St Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.